000 02278nam a22003615i 4500
001 276947
003 MX-SnUAN
005 20160429153755.0
007 cr nn 008mamaa
008 150903s2012 gw | o |||| 0|eng d
020 _a9783642249808
_99783642249808
024 7 _a10.1007/9783642249808
_2doi
035 _avtls000358160
039 9 _a201509031013
_bVLOAD
_c201405070226
_dVLOAD
_y201402191515
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aQR46
100 1 _aKotb, Essam.
_eautor
_9299230
245 1 0 _aFibrinolytic Bacterial Enzymes with Thrombolytic Activity /
_cby Essam Kotb.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg,
_c2012.
300 _axii, 74 páginas 15 ilustraciones, 6 ilustraciones en color.
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aSpringerBriefs in Microbiology
500 _aSpringer eBooks
520 _aStress, high blood pressure, smoking, pollution, fast foods, overweight, excessive travelling, surgery, less movement are common features in our modern life. These features are risky for blood clotting disorders. According to WHO, over 29% of the total mortalities worldwide are due to thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause an estimated 25 million deaths per year, thus antithrombotic therapy is of great interest. The available thrombolytic agents such as urokinase are highly expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic. Therefore, the production of fibrinolysing enzymes, which rapidly dissolute thrombi within the vascular tree, without the detriments by microorganisms, as described in this book, is the desirable aim of today’s research.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783642249792
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-642-24980-8
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c276947
_d276947